Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wednesday, 26 July 2023 at 07:00 am CEST.
Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation which will follow at 2:00 pm CEST
with Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the
financial and operating results as well as the next milestones of the
Company.
Live conference call and video webcast presentation:
Date: Wednesday, 26 July 2023
Time: 2:00 pm CEST
Participant webcast link: Chrome (recommended) or Firefox
https://media.choruscall.eu/mediaframe/webcast.html?webcastid=cjTWeUeO
Please note that there is a function to type in your questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone, may call the
following numbers below. To ensure prompt access, please call
approximately ten minutes prior to the scheduled start of the call.
| Switzerland / Europe |
+41 (0) 58 310 50 00 |
| United Kingdom |
+44 (0) 207 107 06 13 |
| United States |
+1 (1) 631 570 56 13 |
The media release as well as the Half-Year Report 2023 will be available for download as of 07:00 am CEST on 26 July 2023 at www.cosmopharma.com.
Replay
The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
About Cosmo
Cosmo is a pharmaceutical company focused on developing and
commercializing products to treat selected gastrointestinal disorders,
to improve endoscopy quality measures through aiding the detection of
colonic lesions and to treat selected dermatological conditions. Cosmo
develops and manufactures products which are distributed globally by
selected partners including Lialda®/Mezavant®/Mesavancol®,
Uceris®/Cortiment®, Aemcolo®/ Relafalk® and Winlevi®. Cosmo has also
developed medical devices for endoscopy and has a partnership with
Medtronic for the global distribution of GI Genius™ which uses
artificial intelligence to help detect potential signs of colon cancer.
The company also has a rich development pipeline. For additional
information on Cosmo and its products, please visit www.cosmopharma.com.
